Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.
Science, 2010/1/08;327(5962):198-201.
Lanford RE[1], Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H
Affiliations
PMID: 19965718DOI: 10.1126/science.1178178
Impact factor: 63.714
Abstract
The liver-expressed microRNA-122 (miR-122) is essential for hepatitis C virus (HCV) RNA accumulation in cultured liver cells, but its potential as a target for antiviral intervention has not been assessed. We found that treatment of chronically infected chimpanzees with a locked nucleic acid (LNA)-modified oligonucleotide (SPC3649) complementary to miR-122 leads to long-lasting suppression of HCV viremia, with no evidence of viral resistance or side effects in the treated animals. Furthermore, transcriptome and histological analyses of liver biopsies demonstrated derepression of target mRNAs with miR-122 seed sites, down-regulation of interferon-regulated genes, and improvement of HCV-induced liver pathology. The prolonged virological response to SPC3649 treatment without HCV rebound holds promise of a new antiviral therapy with a high barrier to resistance.
MeSH terms
Animals; Antiviral Agents; Chemokine CXCL10; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Viral; Female; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Interferons; Liver; Male; MicroRNAs; Oligonucleotides; Pan troglodytes; Phosphorothioate Oligonucleotides; RNA, Messenger; RNA, Viral; Viral Load; Viremia
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download